$DYAI

Francisco Trust under agreement dated February 28, 1996 sold $125K of DYAI

Francisco Trust under agreement dated February 28, 1996 sold 95,392 shares of DYADIC INTERNATIONAL INC (DYAI) at an average of $1.31 ($1.21–$1.33, $0.12M total) across 3 trades over 2026-07-22 to 2026-07-24.

Original reporting
SEC EDGAR · Francisco Trust under agreement dated February 28, 1996
Published Jul 24, 2026, 9:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DYAI
Bearish
medium confidence
Mentioned
$DYAI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DYAIBearishLow
01

Why it matters

The disclosure may slightly pressure sentiment due to insider selling, but it does not provide new operational or financial information about DYAI.

02

Market read

Traders may monitor DYAI for follow-on insider activity, but the filing alone is unlikely to drive a major repricing without accompanying company news.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on total holdings, tax planning, or whether other insiders sold/bought around the same time.

Relevance 4/10Novelty 3/10Timing: Filed on 2026-07-24, covering sales from 2026-07-22 to 2026-07-24.

Background

This is an SEC Form 4 insider transaction by a 10% owner for Dyadic International Inc (DYAI).

Company-level read

Ticker impact

$DYAIBearishMedium confidence
Context

Form 4 shows 10% owner Francisco Trust sold 95,392 DYAI shares in open-market trades for about $124,958.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or company-specific news.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no new company fundamentals, guidance, or event beyond the sale details.

Market effects

No sector-level implications; this is a single-company insider sale disclosure.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management, especially since the filing does not indicate distress or a company event.

Key entities

  • DYADIC INTERNATIONAL INC

    Company whose shares were sold by a 10% owner insider, per SEC Form 4.

  • Francisco Trust

    10% owner who executed open-market sales of DYAI shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DYAIMed

DYAI: Second Quarter Results

Dyadic (DYAI) reported $4.7M cash and short-term securities at June 30, 2026, down from $8.6M at end-2025, with $3.8M cash burn in the first half of 2026. After its Q2 report, it announced a $2.9M registered direct offering and private placement, expecting $2.28M net proceeds, plus an ATM with Craig-Hallum. The company also updated multiple partnerships and noted going-concern doubt.

$DYAIMedAI 8/10

Dyadic International Raises $2.9 Million in Registered Direct and Concurrent Warrant Offering

Dyadic International said it raised about $2.9 million via a registered direct offering and a concurrent private placement of warrants. The company will sell 3.625 million common shares at $0.795 and issue 3.625 million warrants at $0.005 each, exercisable at $0.84. Proceeds will support general corporate uses, including R&D and working capital, with Aegis Capital as placement agent.

$DYAIMedAI 8/10

Dyadic International (NASDAQ: DYAI) prices $2.9M stock sale and warrant placement

Dyadic International (NASDAQ: DYAI) entered into agreements on Aug. 13, 2026 for a registered direct offering and concurrent private placement. It will sell 3,625,000 shares at $0.795/share and issue warrants to buy 3,625,000 shares with a $0.84 exercise price. Gross proceeds are expected at about $2.9 million, before expenses, for general corporate purposes.

$DYAIMedAI 8/10

DYADIC INTERNATIONAL INC (DYAI): Results of Operations and Financial Condition

DYADIC INTERNATIONAL INC (DYAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DYADIC ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS ACCELERATING COMMERCIALIZATION MOMENTUM ACROSS KEY BUSINESS AREAS Dyadic to host earnings call on August 12 at 5:00 pm ET JUPITER, FL — August 12, 2026 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, o

$DYAIMedAI 8/10

Dyadic International Hits Inflection Point as Product Launches Drive Commercial Shift

Dyadic International (NASDAQ:DYAI) said at the Lytham Partners Spring 2026 Investor Conference that it has shifted from an R&D and licensing focus to a commercial-stage protein and enzyme business. It has launched six products in 12 months and secured global distribution and partner deals, including purchase orders for transferrin. The company expects 2026 to be a launch year and reported nearly $3.5 million in upfront milestone fees from Proliant and Inzymes.

$DYAIMedAI 8/10

Dyadic International, Inc.: Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Dyadic International (NASDAQ: DYAI) said it is collaborating with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, associated with Hantavirus Pulmonary Syndrome. The companies plan to assess Dyadic’s C1 microbial platform for rapid, scalable biologic manufacturing, building on prior Andes work and earlier GMP/Phase 1 C1-produced biologics.